Acumen Pharmaceuticals announced the publication of results from its Phase 1 INTERCEPT-AD clinical trial in the Journal of Prevention of Alzheimer’s Disease. The publication detailed that sabirnetug was generally well-tolerated and demonstrated dose- and exposure-dependent target engagement.
The study also showed a statistically significant reduction in amyloid plaques within higher dose cohorts and reported low overall levels of Amyloid-Related Imaging Abnormalities-Edema (ARIA-E). These findings provide important evidence of sabirnetug’s safety profile and confirm its mechanism of action.
The robust data package from this Phase 1 study establishes the foundation for the ongoing Phase 2 ALTITUDE-AD clinical trial. Enrollment for the Phase 2 trial is expected to be completed in the first half of 2025, building on these positive early results.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.